Abstract Number: 025 • 2023 Pediatric Rheumatology Symposium
Patient- and Center-level Risk Factors for Research Lost to Follow-up Using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: Clinical registries are typically envisioned to be representative of a target patient population and reflective of health care delivery practices for said population. Variation…Abstract Number: 059 • 2023 Pediatric Rheumatology Symposium
Update of Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem. Despite recent advances, there remain key unanswered questions…Abstract Number: 062 • 2023 Pediatric Rheumatology Symposium
Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
Background/Purpose: Since 2010, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) has developed 12 consensus treatment plans (CTP) with the aim of reducing treatment variability…Abstract Number: 109 • 2023 Pediatric Rheumatology Symposium
Long-term Safety of Biologics versus Conventional Synthetic Treatments in Systemic Juvenile Idiopathic Arthritis Patients
Background/Purpose: The better understanding of systemic Juvenile Idiopathic Arthritis (sJIA) pathogenesis and availability of new drugs, such as biologic disease-modifying anti-rheumatic drugs (bDMARDs) specifically dedicated…Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium
Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…Abstract Number: L09 • ACR Convergence 2022
Impact on Access to Methotrexate in the Post-Roe Era
Background/Purpose: Methotrexate is the first line therapy for RA and is used to treat several other rheumatic and non-rheumatic disorders. In high doses, it can…Abstract Number: 0072 • ACR Convergence 2022
Geographical Patterns of Healthcare Utilization Among RA and OA Patients
Background/Purpose: Rural residence has been associated with disparities in healthcare-related outcomes in both rheumatic diseases and other chronic conditions. A primary causal pathway for this…Abstract Number: 1218 • ACR Convergence 2022
Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry
Background/Purpose: Fibromyalgia (FM) occurs concomitantly with inflammatory rheumatic disease, including psoriatic arthritis (PsA), in up to 20% of patients and chronic widespread pain (CWP) in…Abstract Number: 0258 • ACR Convergence 2022
Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents
Background/Purpose: Interstitial lung disease (ILD) is a spectrum of inflammatory and fibrotic lung diseases, and can be associated with RA (RA-ILD). The reported prevalence in…Abstract Number: 1308 • ACR Convergence 2022
Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study
Background/Purpose: Patients with sarcoidosis are at an increased risk of developing osteoporosis due to the active inflammatory state and chronic corticosteroid use. Proper dosing of…Abstract Number: 0289 • ACR Convergence 2022
Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and was approved under Taiwan's National Health Insurance (NHI) reimbursement system in…Abstract Number: 1318 • ACR Convergence 2022
Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on Bone Mineral Density: Baseline Findings in a Cohort of Rheumatic Disease Patients with Prior Glucocorticoid Exposure
Background/Purpose: Inflammatory rheumatic and musculoskeletal diseases (iRMD) are associated with increased systemic bone loss that is mediated by chronic inflammation, treatment with glucocorticoids (GC), and…Abstract Number: 0290 • ACR Convergence 2022
Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)
Background/Purpose: The "ORAL Surveillance" study1 suggests an increased risk of serious adverse events (AEs) with tofacitinib, a JAK-inhibitor (JAKi), compared to TNF-inhibitors (TNFi). Currently, there…Abstract Number: 1380 • ACR Convergence 2022
Development of Core and Expanded Datasets to Align Registries and Advance International Collaborative Research for Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) occurs in approximately 20% of all SLE cases. cSLE is has a worse prognosis than adult-onset SLE, often requiring…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 18
- Next Page »